KPV
KPV is the Lys-Pro-Val tail of alpha-MSH. Its strongest direct evidence is cell and animal work, especially experimental colitis. Transport across excised human skin is not a human treatment study, and the cited records include no administered-human outcome trial.
alpha-MSH-derived tripeptide
- Three-amino-acid peptide: Lys-Pro-Val
- Mouse colitis studies used free peptide or engineered delivery systems
- Human-skin paper tested laboratory permeation across excised tissue
- No FDA-approved KPV drug
What exactly is KPV?
KPV is the tripeptide Lys-Pro-Val, corresponding to the C-terminal three residues of alpha-MSH. Free KPV, a salt, a nanoparticle cargo, and a seller’s finished product are not automatically equivalent interventions.
The sequence is short, but the formulation still matters. Several of the strongest animal papers solved delivery with nanoparticles, hydrogels, microporation, or iontophoresis. Those technologies are part of what was tested.
KPV · cells and mouse colitis
Cell and animal study
Dalmasso G et al. Gastroenterology, 2008.
KPV was transported by the peptide transporter PepT1 in intestinal cell systems and reduced inflammatory signaling and experimental colitis findings in mice. The work supports a gut-delivery mechanism in models, not treatment efficacy in people.
- Participants / model
- Intestinal cell systems and mouse colitis models
- Treatment
- KPV under experimental conditions
- Study design
- Mechanistic cell work plus animal intervention
FDA 2026 briefing · KPV evidence review
FDA staff briefing document
US Food and Drug Administration, July 2026.
FDA staff reviewed KPV identity, animal and formulation evidence, and the absence of adequate human safety and efficacy evidence, then recommended against adding KPV to the 503A bulks list. The advisory process did not approve KPV.
- Study design
- Regulatory evidence review
Has KPV been tested as a treatment in people?
The cited PubMed and ClinicalTrials.gov records include no exact administered-human KPV treatment study under the listed aliases. A study using excised human skin measured transport, not safety or clinical benefit in a living person.
Human cells and human tissue can answer mechanistic or delivery questions. They do not provide adverse-event rates, effective exposure, symptom outcomes, or interactions in patients.
Does the skin study prove a topical product works?
No. It combined microporation and electrical iontophoresis in an ex-vivo system. It did not test ordinary cream, intact living skin, inflammation, or a patient outcome.
Excised skin · permeation, not treatment
Ex-vivo formulation study
Pawar K et al. Journal of Pharmaceutical Sciences, 2017.
Researchers measured KPV transport using iontophoresis across microporated human skin in a laboratory setup. The experiment addressed delivery feasibility and did not administer KPV to a person or measure a clinical skin outcome.
- Participants / model
- Excised human skin in a laboratory diffusion system
- Treatment
- Microporation plus iontophoresis of KPV
- Study design
- Ex-vivo permeation experiment
The experiment used excised tissue and did not administer KPV to a person.
Read the original sourceExcised skin · permeation, not treatment
Ex-vivo formulation study
Pawar K et al. Journal of Pharmaceutical Sciences, 2017.
Researchers measured KPV transport using iontophoresis across microporated human skin in a laboratory setup. The experiment addressed delivery feasibility and did not administer KPV to a person or measure a clinical skin outcome.
- Participants / model
- Excised human skin in a laboratory diffusion system
- Treatment
- Microporation plus iontophoresis of KPV
- Study design
- Ex-vivo permeation experiment
The experiment used excised tissue and did not administer KPV to a person.
Read the original sourcePubMed and registry · no exact administered-human study
PubMed and ClinicalTrials.gov records
PubMed and ClinicalTrials.gov records for KPV peptide and Lys-Pro-Val.
The cited records include no registered trial administering an exact KPV drug product to people under KPV peptide or Lys-Pro-Val. Acronym and amino-acid false positives are unrelated records.
Read the original sourceFDA safety page · no human exposure data
FDA safety communication
US Food and Drug Administration.
FDA states that it had not identified human exposure data for drug products containing KPV by any route and lacked enough information to determine whether KPV would cause harm in humans.
- Study design
- Agency safety summary
What do the colitis studies show?
KPV reduced inflammatory findings in cell systems and mouse colitis models. Colon-targeted nanoparticles also worked in mice, but that result belongs to the full delivery system and cannot be assigned to a generic oral capsule.
The PepT1 work supports uptake and anti-inflammatory signaling in intestinal models. Other papers invoke melanocortin receptors, NF-kappa-B, or receptor-independent actions. The dominant human mechanism is not established.
Is KPV proven to treat inflammatory bowel disease?
KPV reduced inflammatory findings in induced mouse colitis, including studies that used targeted delivery systems. No controlled patient trial establishes that it treats inflammatory bowel disease.
KPV · cells and mouse colitis
Cell and animal study
Dalmasso G et al. Gastroenterology, 2008.
KPV was transported by the peptide transporter PepT1 in intestinal cell systems and reduced inflammatory signaling and experimental colitis findings in mice. The work supports a gut-delivery mechanism in models, not treatment efficacy in people.
- Participants / model
- Intestinal cell systems and mouse colitis models
- Treatment
- KPV under experimental conditions
- Study design
- Mechanistic cell work plus animal intervention
KPV nanoparticles · mouse DSS colitis
Animal drug-delivery study
Laroui H et al. Gastroenterology, 2010.
KPV loaded into a polysaccharide hydrogel and nanoparticle delivery system reduced disease measures in a mouse colitis model. The carrier, colon targeting, species, and induced-disease model are part of the intervention.
- Participants / model
- Mice with experimentally induced colitis
- Treatment
- KPV-loaded colon-targeted nanoparticles in hydrogel
- Study design
- Controlled animal formulation study
The result does not establish that free oral KPV survives and reaches the same target in people.
Read the original sourceKPV · cells and mouse colitis
Cell and animal study
Dalmasso G et al. Gastroenterology, 2008.
KPV was transported by the peptide transporter PepT1 in intestinal cell systems and reduced inflammatory signaling and experimental colitis findings in mice. The work supports a gut-delivery mechanism in models, not treatment efficacy in people.
- Participants / model
- Intestinal cell systems and mouse colitis models
- Treatment
- KPV under experimental conditions
- Study design
- Mechanistic cell work plus animal intervention
KPV nanoparticles · mouse DSS colitis
Animal drug-delivery study
Laroui H et al. Gastroenterology, 2010.
KPV loaded into a polysaccharide hydrogel and nanoparticle delivery system reduced disease measures in a mouse colitis model. The carrier, colon targeting, species, and induced-disease model are part of the intervention.
- Participants / model
- Mice with experimentally induced colitis
- Treatment
- KPV-loaded colon-targeted nanoparticles in hydrogel
- Study design
- Controlled animal formulation study
The result does not establish that free oral KPV survives and reaches the same target in people.
Read the original sourceWhat is known about KPV safety?
There is no usable human adverse-event dataset for administered KPV. Immune effects, pregnancy, infection, allergy, interactions, repeated exposure, and route-specific toxicity remain unknown.
- Anti-inflammatory activity: no human infection data show whether defense against pathogens remains intact.
- Melanocortin assumptions: KPV is not proven free of pigment, appetite, endocrine, or off-target effects simply because it is shorter than alpha-MSH.
- Compounded or seller products: identity, concentration, sterility, endotoxin, and degradation data are separate from peptide-sequence claims.
PubMed and registry · no exact administered-human study
PubMed and ClinicalTrials.gov records
PubMed and ClinicalTrials.gov records for KPV peptide and Lys-Pro-Val.
The cited records include no registered trial administering an exact KPV drug product to people under KPV peptide or Lys-Pro-Val. Acronym and amino-acid false positives are unrelated records.
Read the original sourceFDA safety page · no human exposure data
FDA safety communication
US Food and Drug Administration.
FDA states that it had not identified human exposure data for drug products containing KPV by any route and lacked enough information to determine whether KPV would cause harm in humans.
- Study design
- Agency safety summary
Did the 2026 FDA review approve KPV?
No. FDA staff recommended against 503A bulks-list inclusion, and the advisory process did not create drug approval. The cited FDA records list no approved KPV product or dosing label.
A nomination, committee discussion, or vote is not evidence of efficacy and does not establish that a seller product may be marketed as a treatment.
FDA 2026 briefing · KPV evidence review
FDA staff briefing document
US Food and Drug Administration, July 2026.
FDA staff reviewed KPV identity, animal and formulation evidence, and the absence of adequate human safety and efficacy evidence, then recommended against adding KPV to the 503A bulks list. The advisory process did not approve KPV.
- Study design
- Regulatory evidence review
FDA safety page · no human exposure data
FDA safety communication
US Food and Drug Administration.
FDA states that it had not identified human exposure data for drug products containing KPV by any route and lacked enough information to determine whether KPV would cause harm in humans.
- Study design
- Agency safety summary
Studies and sources
KPV · cells and mouse colitis
Cell and animal study
Dalmasso G et al. Gastroenterology, 2008.
KPV was transported by the peptide transporter PepT1 in intestinal cell systems and reduced inflammatory signaling and experimental colitis findings in mice. The work supports a gut-delivery mechanism in models, not treatment efficacy in people.
- Participants / model
- Intestinal cell systems and mouse colitis models
- Treatment
- KPV under experimental conditions
- Study design
- Mechanistic cell work plus animal intervention
KPV nanoparticles · mouse DSS colitis
Animal drug-delivery study
Laroui H et al. Gastroenterology, 2010.
KPV loaded into a polysaccharide hydrogel and nanoparticle delivery system reduced disease measures in a mouse colitis model. The carrier, colon targeting, species, and induced-disease model are part of the intervention.
- Participants / model
- Mice with experimentally induced colitis
- Treatment
- KPV-loaded colon-targeted nanoparticles in hydrogel
- Study design
- Controlled animal formulation study
The result does not establish that free oral KPV survives and reaches the same target in people.
Read the original sourceExcised skin · permeation, not treatment
Ex-vivo formulation study
Pawar K et al. Journal of Pharmaceutical Sciences, 2017.
Researchers measured KPV transport using iontophoresis across microporated human skin in a laboratory setup. The experiment addressed delivery feasibility and did not administer KPV to a person or measure a clinical skin outcome.
- Participants / model
- Excised human skin in a laboratory diffusion system
- Treatment
- Microporation plus iontophoresis of KPV
- Study design
- Ex-vivo permeation experiment
The experiment used excised tissue and did not administer KPV to a person.
Read the original sourcePubMed and registry · no exact administered-human study
PubMed and ClinicalTrials.gov records
PubMed and ClinicalTrials.gov records for KPV peptide and Lys-Pro-Val.
The cited records include no registered trial administering an exact KPV drug product to people under KPV peptide or Lys-Pro-Val. Acronym and amino-acid false positives are unrelated records.
Read the original sourceFDA safety page · no human exposure data
FDA safety communication
US Food and Drug Administration.
FDA states that it had not identified human exposure data for drug products containing KPV by any route and lacked enough information to determine whether KPV would cause harm in humans.
- Study design
- Agency safety summary
FDA 2026 briefing · KPV evidence review
FDA staff briefing document
US Food and Drug Administration, July 2026.
FDA staff reviewed KPV identity, animal and formulation evidence, and the absence of adequate human safety and efficacy evidence, then recommended against adding KPV to the 503A bulks list. The advisory process did not approve KPV.
- Study design
- Regulatory evidence review
Why is KPV in B tier?
B reflects consistent anti-inflammatory findings in cell and animal models. No administered-human trial establishes efficacy, route, or safety for oral, injected, nasal, or topical products.